《中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)》解读

梁贇; 吴文铭; 聂勇战; 陈洁

doi:10.12290/xhyxzz.2022-0607

《中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)》解读

doi: 10.12290/xhyxzz.2022-0607

梁贇^{1, 2},
吴文铭^3, ,,
聂勇战^4, ,,
陈洁^{1, 2, ,}

1.
复旦大学附属肿瘤医院神经内分泌肿瘤中心头颈及神经内分泌肿瘤内科, 上海 200032
2.
复旦大学上海医学院肿瘤学系，上海 200032
3.
中国医学科学院北京协和医院基本外科，北京 100730
4.
空军军医大学西京医院消化内科，西安 710032

基金项目:

国家自然科学基金 82141104

详细信息

通讯作者:
吴文铭, E-mail：wuwm@pumch.cn

聂勇战, E-mail：yongznie@fmmu.edu.cn

陈洁, E-mail：chen0jie@hotmail.com

中图分类号: R730.4; R730.5
计量
- 文章访问数: 811
- HTML全文浏览量: 101
- PDF下载量: 364
- 被引次数: 0
出版历程
- 收稿日期: 2022-10-18
- 录用日期: 2022-12-05
- 网络出版日期: 2023-01-16
- 刊出日期: 2023-01-30

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

LIANG Yun^{1, 2},
WU Wenming^{3
, ,},
NIE Yongzhan^{4
, ,},
CHEN Jie^{1, 2
, ,}

1.
Center for Neuroendocrine Tumors, Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3.
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
4.
Department of Gastroenterology, Xijing Hospital, Air Force Medical University, Xi'an 710032, China

Funds:

National Natural Science Foundation of China 82141104

More Information

Corresponding author: WU Wenming, E-mail: wuwm@pumch.cn; NIE Yongzhan, E-mail: yongznie@fmmu.edu.cn; CHEN Jie, E-mail: chen0jie@hotmail.com

摘要

摘要: 神经内分泌肿瘤是起源于肽能神经元和神经内分泌细胞的少见肿瘤，具有较高的异质性，临床诊断和治疗复杂。中国抗癌协会神经内分泌肿瘤专业委员会组织相关领域专家，在现有循证医学证据基础上，结合国内外相关指南和共识，制定了首版神经内分泌肿瘤诊治指南。本文旨在对指南的重点内容进行解读，并针对部分争议问题进行讨论，以期为临床实践提供借鉴和参考。
- 神经内分泌肿瘤 /
- 诊断 /
- 治疗 /
- 指南 /
- 解读
Abstract: Neuroendocrine neoplasms (NENs) are a group of malignancies arising from neuroendocrine cells and peptidergic neurons. The high heterogeneity of NENs leads to challenges and complexities in its diagnosis and treatment. Experts from relevant disciplines were convened by the Society of Neuroendocrine neoplasm of China Anti-Cancer Association to develop this first edition of the Chinese Guideline for diagnosis and treatment of NENs (2022) based on existing evidence combined with domestic and international guidelines and consensus. In this article, we summarize the important contents of this guideline and make further discussion on some controversial issues, with the aim to provide treatment reference in clinical practice.
- neuroendocrine neoplasms /
- diagnosis /
- treatment /
- guideline /
- interpretation
注释:

作者贡献：梁贇负责论文撰写；陈洁、聂勇战、吴文铭负责论文审校和修订。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

参考文献(38)

[1]	Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States[J]. JAMA Oncol, 2017, 3: 1335-1342. doi: 10.1001/jamaoncol.2017.0589
[2]	Fang C, Wang W, Zhang Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China[J]. Chin J Cancer, 2017, 36: 51. doi: 10.1186/s40880-017-0218-3
[3]	Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Func-tional Pancreatic Neuroendocrine Tumors[J]. Neuroendocrinology, 2016, 103: 153-171. doi: 10.1159/000443171
[4]	Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis[J]. Front Endocrinol (Lausanne), 2019;10: 339. doi: 10.3389/fendo.2019.00339
[5]	Puliani G, Di Vito V, Feola T, et al. NETest: A Systematic Review Focusing on the Prognostic and Predictive Role[J]. Neuroendocrinology, 2022, 112: 523-536. doi: 10.1159/000518873
[6]	Malczewska A, Kos-Kudła B, Kidd M, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors[J]. Adv Med Sci, 2020, 65: 18-29. doi: 10.1016/j.advms.2019.10.002
[7]	Chen L, Guo Y, Zhang Y, et al. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors[J]. Endoscopy, 2021, 53: 702-709. doi: 10.1055/a-1274-0161
[8]	Luo Y, Chen J, Huang K, et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?[J]. BMC Cancer, 2017, 17: 154. doi: 10.1186/s12885-017-3150-7
[9]	Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study)[J]. Br J Cancer, 2019, 121: 537-544. doi: 10.1038/s41416-019-0558-7
[10]	Chen L, Wang W, Jin K, et al. Special issue "the advane of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors[J]. Int J Cancer, 2023, 152: 90-99. doi: 10.1002/ijc.34294
[11]	Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and ¹⁸F-FDG[J]. Cancer, 2008, 112: 2447-2455. doi: 10.1002/cncr.23469
[12]	Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of the Impact of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors[J]. J Nucl Med, 2016, 58: 91-96.
[13]	Rinzivillo M, Partelli S, Prosperi D, et al. Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms[J]. Oncologist, 2018, 23: 186-192. doi: 10.1634/theoncologist.2017-0278
[14]	Kim YI, Yoo C, Oh SJ, et al. Tumour-to-liver ratio determined by[(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours[J]. EJNMMI Res, 2020, 10: 63. doi: 10.1186/s13550-020-00651-z
[15]	Kuik WJ, Kema IP, Brouwers AH, et al. In vivo biodistribution of no-carrier-added 6-¹⁸F-fluoro-3, 4-dihydroxy-L-phenylalanine (¹⁸F-DOPA), produced by a new nucleo-philic substitution approach, compared with carrier-added (¹⁸F-DOPA), prepared by conventional electrophilic substitution[J]. J Nucl Med, 2015, 56: 106-112. doi: 10.2967/jnumed.114.145730
[16]	Piccardo A, Lopci E, Conte M, et al. Comparison of ¹⁸F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study[J]. Eur J Nucl Med Mol Imaging, 2012, 39: 57-71. doi: 10.1007/s00259-011-1938-2
[17]	Luo Y, Pan Q, Yao S, et al. Glucagon-like Peptide-1 Receptor PET/CT with ⁶⁸Ga-NOTA-exendin-4 for Detecting Localized Insulinoma: a Prospective Cohort Study[J]. J Nucl Med, 2016, 57: 715-720. doi: 10.2967/jnumed.115.167445
[18]	WHO Classification of Tumours Editorial Board. WHO classification of tumours, 5th Edition, Volume 1: Digestive System Tumours[M]. Lyon: IARC Press, 2019.
[19]	WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th Edition, Volume 5: Thoracic Tumours[M]. Lyon: IARC Press, 2021.
[20]	Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart[J]. J Thorac Oncol, 2015, 10: 1240-1242. doi: 10.1097/JTO.0000000000000663
[21]	Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal[J]. Mod Pathol, 2018, 31: 1770-1786. doi: 10.1038/s41379-018-0110-y
[22]	Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms[J]. Endocr Pathol, 2022, 33: 115-154. doi: 10.1007/s12022-022-09708-2
[23]	Chivukula SV, Tierney JF, Hertl M, et al. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over-or undertreating patients?[J]. Surgery, 2020, 167: 180-186. doi: 10.1016/j.surg.2019.04.061
[24]	Dong DH, Zhang XF, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm after curative resection: A multi-institutional study of 392 cases[J]. J Surg Oncol, 2019, 120: 1071-1079. doi: 10.1002/jso.25716
[25]	Lopez-Aguiar AG, Zaidi MY, Beal EW, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: An eight-institution study of 695 patients from the US neuroendocrine tumor study group[J]. Ann Surg Oncol, 2019, 26: 2517-2524. doi: 10.1245/s10434-019-07367-y
[26]	Guarneri G, de Mestier L, Landoni L, et al. Prognostic role of examined and positive lymph nodes after distal pancreatectomy for non-functioning neuroendocrine neoplasms[J]. Neuroendocrinology, 2021, 111: 728-738. doi: 10.1159/000509709
[27]	Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371: 224-233. doi: 10.1056/NEJMoa1316158
[28]	Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroen-docrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27: 4656-4663. doi: 10.1200/JCO.2009.22.8510
[29]	Liu Y, Liu H, Chen W, et al. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden[J]. Cancer Med, 2022, 11: 2588-2600. doi: 10.1002/cam4.4628
[30]	Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?[J]. J Hepatol, 2007, 47: 460-466. doi: 10.1016/j.jhep.2007.07.004
[31]	中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32: 545-580. Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. Zhongguo Aizheng Zazhi, 2022, 32: 545-580.
[32]	Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas[J]. Neuroendocrinology, 2016, 103: 186-194. doi: 10.1159/000443172
[33]	National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors (Version 2021)[EB/OL]. [2021-06-18]. https://www.nccn.org/guidelines/guidelines-detail?cate-gory=1&id=1448.
[34]	Bongiovanni A, Liverani C, Foca F, et al. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis[J]. Neuroendocrinology, 2021, 111: 895-906. doi: 10.1159/000513218
[35]	Wang W, Zhang Y, Peng Y, et al. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolo-mide Regimen in Neuroendocrine Neoplasms: A Retrospec-tive Multicenter Study[J]. Neuroendocrinology, 2021, 111: 752-763. doi: 10.1159/000510159
[36]	Apostolidis L, Dal Buono A, Merola E, et al. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)[J]. Cancers, 2021, 13: 1936. doi: 10.3390/cancers13081936
[37]	Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379: 2220-2229. doi: 10.1056/NEJMoa1809064
[38]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394: 1929-1939. doi: 10.1016/S0140-6736(19)32222-6

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 811
HTML全文浏览量: 101
PDF下载量: 364
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

《中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)》解读

doi: 10.12290/xhyxzz.2022-0607

通讯作者:
吴文铭, E-mail：wuwm@pumch.cn

聂勇战, E-mail：yongznie@fmmu.edu.cn

陈洁, E-mail：chen0jie@hotmail.com

计量

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

Corresponding author: WU Wenming, E-mail: wuwm@pumch.cn; NIE Yongzhan, E-mail: yongznie@fmmu.edu.cn; CHEN Jie, E-mail: chen0jie@hotmail.com

计量

目录

留言板

《中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)》解读

doi: 10.12290/xhyxzz.2022-0607

通讯作者: 吴文铭, E-mail：wuwm@pumch.cn 聂勇战, E-mail：yongznie@fmmu.edu.cn 陈洁, E-mail：chen0jie@hotmail.com

计量

出版历程

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

Corresponding author: WU Wenming, E-mail: wuwm@pumch.cn; NIE Yongzhan, E-mail: yongznie@fmmu.edu.cn; CHEN Jie, E-mail: chen0jie@hotmail.com

计量

出版历程

目录

通讯作者:
吴文铭, E-mail：wuwm@pumch.cn

聂勇战, E-mail：yongznie@fmmu.edu.cn

陈洁, E-mail：chen0jie@hotmail.com